HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.

Abstract
Eight anthracycline analogs that have been shown to modulate multidrug resistance (Friche et al., Biochem. Pharmacol., 39, 1721-1726; 1990) were tested for their inhibitory effect on the photolabelling of P-glycoprotein. We photoaffinity labelled P-glycoprotein in daunorubicin (DNR) resistant Ehrlich ascites tumour cells (EHR2/DNR +) with a [125I]iodinated Bolton-Hunter derivative of daunorubicin ([125I]iodomycin) and with [3H]azidopine. The photolabelling of P-glycoprotein by [125I]iodomycin was inhibited more than 50% by 10 microM (1000-fold molar excess) of DNR (52%), N,N-dibenzyl-DNR (52%), and N-benzyladriamycin-14-valerate (AD-198) (85%). Vincristine at 10 microM inhibited [125I]iodomycin labelling of P-glycoprotein by 95%. Thus vincristine was more potent than any of the eight anthracyclines tested, despite its relatively low lipophilicity. Increasing the concentration of DNR, AD-198 and N,N-dibenzyl-DNR to 40 microM resulted in 90, 99.5 and 99.5% inhibition of P-glycoprotein labelling by [125I]iodomycin, respectively. In comparison with the other anthracycline analogs, N,N-dibenzyl-DNR and Ad-198 were also found to exert the greatest inhibition of [3H]azidopine labelling of P-glycoprotein (about 90% at 100-fold molar excess). The solvents Cremophor EL and Tween 80 (30 micrograms ml-1; 0.003% v/v), which are modulators of multidrug resistance in EHR2/DNR + cells, also inhibited [125I]iodomycin labelling > 90%. We showed earlier that there is a correlation between the lipid solubility within the anthracycline group of MDR-associated drugs and their ability to enhance DNR accumulation in EHR2/DNR + cells but a corresponding correlation to lipophilicity when it comes to the inhibitory effect on the specific photolabelling of Pgp ligand binding sites could not be demonstrated. Neither could a correlation between the modulating effect of the analogs on DNR accumulation and inhibition on the labelling of Pgp be demonstrated. With increasing lipophilicity of the analogs it seems that the chemical structure plays a lesser role, and the degree of lipophilicity becomes a more important feature.
AuthorsE Friche, E J Demant, M Sehested, N I Nissen
JournalBritish journal of cancer (Br J Cancer) Vol. 67 Issue 2 Pg. 226-31 (Feb 1993) ISSN: 0007-0920 [Print] England
PMID8094288 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Affinity Labels
  • Antibiotics, Antineoplastic
  • Azides
  • Detergents
  • Dihydropyridines
  • Iodine Radioisotopes
  • Membrane Glycoproteins
  • Tritium
  • iodomycin
  • Vincristine
  • azidopine
  • Doxorubicin
  • N,N-dibenzyldaunorubicin
  • Daunorubicin
Topics
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Affinity Labels
  • Animals
  • Antibiotics, Antineoplastic (pharmacology)
  • Azides (metabolism, pharmacology)
  • Binding, Competitive
  • Biological Transport (drug effects)
  • Carcinoma, Ehrlich Tumor (metabolism)
  • Daunorubicin (analogs & derivatives, metabolism, pharmacokinetics, pharmacology)
  • Detergents (pharmacology)
  • Dihydropyridines (metabolism, pharmacology)
  • Doxorubicin (pharmacology)
  • Drug Resistance
  • Iodine Radioisotopes
  • Membrane Glycoproteins (metabolism)
  • Photochemistry
  • Structure-Activity Relationship
  • Tritium
  • Tumor Cells, Cultured
  • Vincristine (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: